Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272921 · ClinicalTrials.gov registry record · Phase 4
The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block
A Phase 4 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 4
- Development phase
- 142
- Enrollment target
NCT01272921: Completed Phase 4 study, sponsored by Northwestern University.
NCT01272921 is a Phase 4 study that has completed, run by Northwestern University. The registered enrollment target is 142 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01272921, a Phase 4 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 142 participants
- Enrollment target
Study Summary
The duration of motor block for infragluteal parabiceps sciatic nerve block following total knee replacement may vary between 12-36 hrs depending on the amount of local anesthetic given.
Primary Outcome
Subject reported and investigator measured motor and sensory blockade of the sciatic nerve with less than 10ml of 0.5% bupivacaine and ropivacaine after ultrasound-guided nerve-stimulator-assisted needle positioning beneath the common investing external layer (CIEL).
Interventions
- DRUG Bupivacaine
- DRUG Ropivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2010-11 |
| Phase | Phase 4 |
What the finished NCT01272921 record still lists
NCT01272921 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT01272921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01272921 about?
NCT01272921 is a clinical study titled "The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block". The duration of motor block for infragluteal parabiceps sciatic nerve block following total knee replacement may vary between 12-36 hrs depending on the amount of local anesthetic given.
What is the current status of trial NCT01272921?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 142 participants. The study started on 2010-11.
What interventions are being tested in trial NCT01272921?
The interventions under investigation include: Bupivacaine (DRUG), Ropivacaine (DRUG).
Who is sponsoring clinical trial NCT01272921?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01272921's enrollment target sits among peer trials
142 580th of 2000 higher than 1,421 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia